Relevance of pRB Loss in Human Malignancies.
Publication/Presentation Date
1-15-2022
Abstract
The retinoblastoma tumor suppressor protein (pRB) is a known regulator of cell-cycle control; however, recent studies identified critical functions for pRB in regulating cancer-associated gene networks that influence the DNA damage response, apoptosis, and cell metabolism. Understanding the impact of these pRB functions on cancer development and progression in the clinical setting will be essential, given the prevalence of pRB loss of function across disease types. Moreover, the current state of evidence supports the concept that pRB loss results in pleiotropic effects distinct from tumor proliferation. Here, the implications of pRB loss (and resultant pathway deregulation) on disease progression and therapeutic response will be reviewed, based on clinical observation. Developing a better understanding of the pRB-regulated pathways that underpin the aggressive features of pRB-deficient tumors will be essential for further developing pRB as a biomarker of disease progression and for stratifying pRB-deficient tumors into more effective treatment regimens.
Volume
28
Issue
2
First Page
255
Last Page
264
ISSN
1557-3265
Published In/Presented At
Mandigo, A. C., Tomlins, S. A., Kelly, W. K., & Knudsen, K. E. (2022). Relevance of pRB Loss in Human Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 28(2), 255–264. https://doi.org/10.1158/1078-0432.CCR-21-1565
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
34407969
Department(s)
Administration and Leadership
Document Type
Article